Clinical evaluation of pediatric patients with recurrent respiratory papillomatosis.

References

1. 1.↵
   1. Derkay CS,
   2. Wiatrak B

   . Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118: 1236-1247.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Seedat RY

   . Juvenile-onset recurrent respiratory papillomatosis diagnosis and management - a developing country review. Pediatric Health Med Ther 2020; 11: 39-46.

   OpenUrl
3. 3.↵
   1. Venkatesan NN,
   2. Pine HS,
   3. Underbrink MP

   . Recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 45: 671-694.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Orji FT,
   2. Okorafor IA,
   3. Akpeh JO

   . Experience with recurrent respiratory papillomatosis in a developing country: impact of tracheostomy. World J Surg 2013; 37: 339-343.

   OpenUrl
5. 5.↵
   1. Benedict JJ,
   2. Derkay CS

   . Recurrent respiratory papillomatosis: A 2020 perspective. Laryngoscope Investig Otolaryngol 2021; 6: 340-345.

   OpenUrl
6. 6.↵
   1. Rosenberg T,
   2. Philipsen BB,
   3. Mehlum CS,
   4. Dyrvig AK,
   5. Wehberg S,
   6. Chirila M, et al.

   Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis 2019; 219: 1016-1025.

   OpenUrlCrossRef
7. 7.↵
   1. Reeves WC,
   2. Ruparelia SS,
   3. Swanson KI,
   4. Derkay CS,
   5. Marcus A,
   6. Unger ER

   . National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Harshad PL,
   2. Pujari V,
   3. Channappa NM,
   4. Anandaswamy TC

   . Anesthesia management in a child with laryngeal papilloma causing near complete airway obstruction. Saudi J Anaesth 2015; 9: 86-88.

   OpenUrl
9. 9.↵
   1. Ivancic R,
   2. Iqbal H,
   3. deSilva B,
   4. Pan Q,
   5. Matrka L

   . Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018; 3: 22-34.

   OpenUrlPubMed
10. 10.↵
    1. Hoesli RC,
    2. Thatcher AL,
    3. Hogikyan ND,
    4. Kupfer RA

    . Evaluation of safety of intralesional cidofovir for adjuvant treatment of recurrent respiratory papillomatosis. JAMA Otolaryngol Head Neck Surg 2020; 146: 231-236.

    OpenUrl
11. 11.↵
    1. Armbruster C

    . Novel treatments for recurrent respiratory papillomatosis. Expert Opin Investig Drugs 2002; 11: 1139-1148.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. McMurray JS,
    2. Connor N,
    3. Ford CN

    . Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117: 477-483.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Wierzbicka M,
    2. Jackowska J,
    3. Bartochowska A,
    4. Józefiak A,
    5. Szyfter W,
    6. Kędzia W

    . Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2011; 268: 1305-1311.

    OpenUrlPubMed
14. 14.↵
    1. Rahbar R,
    2. Vargas SO,
    3. Folkman J,
    4. McGill TJ,
    5. Healy GB,
    6. Tan X, et al.

    Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 289-295.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Verma H,
    2. Chandran A,
    3. Shaktivel P,
    4. Singh A,
    5. Kaushal S,
    6. Sikka K, et al.

    The serum and tissue expression of vascular endothelial growth factor-in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2021; 146: 110737.

    OpenUrl